Evogene (EVGN) Tops Q2 EPS by 5c

Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $470 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2